NYU Langone Health: Ovarian Neoplasms trials

The registry lists 14 Ovarian Neoplasms studies with NYU Langone Health as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 1 3Phase 2 6No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Irinotecan and Bevacizumab for Recurrent Ovarian CancerCompletedNCT01091259Phase 2Results posted
• Topotecan With Erlotinib for Topotecan Pretreated Ovarian CancerTerminatedNCT01003938Phase 2Results posted
• Imatinib Mesylate (Gleevec) and Paclitaxel in Recurrent Patients of Ovarian and Other Cancers of Mullerian OriginTerminatedNCT00840450Phase 2Results posted
• Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian CancerCompletedNCT03656809
• Prolonged Emend in a Study (NYU 03-67) of Oxaliplatin and Topotecan in Previously Treated Ovarian CancerWithdrawnNCT01017809Not applicable
• Cancer Screening and Prevention Program for High Risk WomenCompletedNCT00849199
• Pharmacokinetic Study of Avastin and Doxil in Ovarian CancerCompletedNCT00846612Phase 1
• Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian Carcinoma Patients at High Risk of ProgressionWithdrawnNCT00659399Phase 1
• NYU Ovarian Cancer Early Detection Program Blood and GeneticsTerminatedNCT00531778
• Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian CarcinomaCompletedNCT00531570
• Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT00006391Phase 1
• Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial CancerCompletedNCT00005051Phase 2
• Liposomal Cisplatin in Treating Patients With Recurrent Ovarian CancerCompletedNCT00004083Phase 2
• Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian CancerCompletedNCT00002671Phase 2